The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics

IF 10.7 Q1 MEDICINE, RESEARCH & EXPERIMENTAL MedComm Pub Date : 2024-07-28 DOI:10.1002/mco2.663
Jian Tang, Yu Chen, Chunhua Wang, Ying Xia, Tingyu Yu, Mengjun Tang, Kun Meng, Lijuan Yin, Yang Yang, Liang Shen, Hui Xing, Xiaogang Mao
{"title":"The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics","authors":"Jian Tang,&nbsp;Yu Chen,&nbsp;Chunhua Wang,&nbsp;Ying Xia,&nbsp;Tingyu Yu,&nbsp;Mengjun Tang,&nbsp;Kun Meng,&nbsp;Lijuan Yin,&nbsp;Yang Yang,&nbsp;Liang Shen,&nbsp;Hui Xing,&nbsp;Xiaogang Mao","doi":"10.1002/mco2.663","DOIUrl":null,"url":null,"abstract":"<p>Mesenchymal stem cells (MSCs) are recruited by malignant tumor cells to the tumor microenvironment (TME) and play a crucial role in the initiation and progression of malignant tumors. This role encompasses immune evasion, promotion of angiogenesis, stimulation of cancer cell proliferation, correlation with cancer stem cells, multilineage differentiation within the TME, and development of treatment resistance. Simultaneously, extensive research is exploring the homing effect of MSCs and MSC-derived extracellular vesicles (MSCs-EVs) in tumors, aiming to design them as carriers for antitumor substances. These substances are targeted to deliver antitumor drugs to enhance drug efficacy while reducing drug toxicity. This paper provides a review of the supportive role of MSCs in tumor progression and the associated molecular mechanisms. Additionally, we summarize the latest therapeutic strategies involving engineered MSCs and MSCs-EVs in cancer treatment, including their utilization as carriers for gene therapeutic agents, chemotherapeutics, and oncolytic viruses. We also discuss the distribution and clearance of MSCs and MSCs-EVs upon entry into the body to elucidate the potential of targeted therapies based on MSCs and MSCs-EVs in cancer treatment, along with the challenges they face.</p>","PeriodicalId":94133,"journal":{"name":"MedComm","volume":null,"pages":null},"PeriodicalIF":10.7000,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11283587/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedComm","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mco2.663","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Mesenchymal stem cells (MSCs) are recruited by malignant tumor cells to the tumor microenvironment (TME) and play a crucial role in the initiation and progression of malignant tumors. This role encompasses immune evasion, promotion of angiogenesis, stimulation of cancer cell proliferation, correlation with cancer stem cells, multilineage differentiation within the TME, and development of treatment resistance. Simultaneously, extensive research is exploring the homing effect of MSCs and MSC-derived extracellular vesicles (MSCs-EVs) in tumors, aiming to design them as carriers for antitumor substances. These substances are targeted to deliver antitumor drugs to enhance drug efficacy while reducing drug toxicity. This paper provides a review of the supportive role of MSCs in tumor progression and the associated molecular mechanisms. Additionally, we summarize the latest therapeutic strategies involving engineered MSCs and MSCs-EVs in cancer treatment, including their utilization as carriers for gene therapeutic agents, chemotherapeutics, and oncolytic viruses. We also discuss the distribution and clearance of MSCs and MSCs-EVs upon entry into the body to elucidate the potential of targeted therapies based on MSCs and MSCs-EVs in cancer treatment, along with the challenges they face.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
间充质干细胞在癌症中的作用及其在癌症治疗中的应用前景。
间充质干细胞(MSCs)被恶性肿瘤细胞招募到肿瘤微环境(TME)中,在恶性肿瘤的发生和发展过程中发挥着至关重要的作用。这种作用包括逃避免疫、促进血管生成、刺激癌细胞增殖、与癌症干细胞相关、在肿瘤微环境中进行多线分化以及产生抗药性。与此同时,大量研究正在探索间充质干细胞和间充质干细胞衍生的细胞外小泡(MSCs-EVs)在肿瘤中的归巢效应,目的是将它们设计成抗肿瘤物质的载体。这些物质可定向递送抗肿瘤药物,在提高药物疗效的同时降低药物毒性。本文综述了间充质干细胞在肿瘤进展中的支持作用以及相关的分子机制。此外,我们还总结了涉及工程间充质干细胞和间充质干细胞-EV 在癌症治疗中的最新治疗策略,包括将它们用作基因治疗药物、化疗药物和溶瘤病毒的载体。我们还讨论了间充质干细胞和间充质干细胞-EV 进入人体后的分布和清除情况,以阐明基于间充质干细胞和间充质干细胞-EV 的靶向疗法在癌症治疗中的潜力及其面临的挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.70
自引率
0.00%
发文量
0
审稿时长
10 weeks
期刊最新文献
Prognostic impact of age on outcomes of hepatic decompensation in patients with compensated cirrhosis (CHESS2102): an international, multicenter cohort study An inflammatory cytokine signature predicts IgA nephropathy severity and progression Immunometabolism: signaling pathways, homeostasis, and therapeutic targets Single-cell transcriptomics reveals IRF7 regulation of the tumor microenvironment in isocitrate dehydrogenase wild-type glioma Targeting the DNA damage response in cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1